BackNLS Pharmaceutics Ltd - Warrants (25/09/2025) Overview

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Receivables

Latest receivables for NLSPW: $540K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$536690.00
1600.16% YoYΔ $505123.00 vs prior year quarter

Peer average

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Receivables History

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) vs. peers: Receivables Comparison

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) (NLSPW) FAQ

NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s receivables stands at $540K as of June 2025. That compares with $32K in the prior-year period — up 1600.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NLS Pharmaceutics Ltd - Warrants (25/09/2025) reported $540K in receivables versus $32K a year earlier — a 1600.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $32K in the prior-year period — up 1600.2% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s receivables evolved across reporting periods, while the comparison chart places NLSPW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s reading of $540K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.